4.3 Article

Improving patient-physician dialog: commentary on the results of the MS Choices survey

Journal

PATIENT PREFERENCE AND ADHERENCE
Volume 6, Issue -, Pages 143-152

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/PPA.S27932

Keywords

multiple sclerosis; treatment adherence; treatment initiation; patient-physician dialog; psychological profiling

Funding

  1. Bayer Schering
  2. Biogen Dompe
  3. Merck Serono
  4. Novartis
  5. Sanofi-Aventis
  6. Teva
  7. Associazione Italiana Sclerosi Multipla
  8. Merck Serono S.A. - Geneva, Switzerland
  9. Merck Serono S.A. Coinsins, Switzerland
  10. Biogen Idec
  11. GSK

Ask authors/readers for more resources

Achieving good long-and short-term adherence to treatment for chronic diseases is important if patients are to gain the full benefits of treatment. Several barriers to adherence in multiple sclerosis (MS) have been identified and the healthcare team should work with patients to help them to overcome these obstacles. The MS Choices survey explored patient and physician perspectives on key aspects of MS diagnosis, treatment adherence, and disease management with the aim of improving understanding of the factors that influence patient behavior regarding treatment adherence. The survey found some important differences between patient and physician responses and here these findings are discussed in the context of personal clinical experience. Further, the possible implications of these findings for routine practice have been considered, and strategies that should be employed by MS physicians and nurses to help patients to adhere to their prescribed treatment are suggested.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available